InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2025-07-13 | Laurel Lee(R-FL15) | house | Purchase | $50,001 - $100,000 |
| 2024-11-25 | Laurel Lee(R-FL15) | house | Purchase | $1,001 - $15,000 |
| 2024-10-18 | Laurel Lee(R-FL15) | house | Sale | $100,001 - $250,000 |
| Metric | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Research and development expenses | $20.5M+54.0% | $13.3M | — | $9.4M | — |
| Acquisition-related costs (note 5) | $3.7M+735.6% | $440K | — | — | — |
| General and administrative expenses | $7.6M+95.8% | $3.9M | — | $4.1M | — |
| Operating Loss | -$31.8M-80.2% | -$17.6M | — | -$29.8M | — |
| Employee Retention Tax Credit | $114K | — | — | — | — |
| Grant income | $714K+1138.1% | $58K | — | $42K | — |
| Interest expense | -$625K+84.9% | -$4.1M | — | -$19K | — |
| Interest income | $136K-62.3% | $362K | — | $90K | — |
| Change in fair value of derivative liability | -$314K | — | — | — | — |
| Change in fair value of Kineta merger holdback shares | $1.6M | — | — | — | — |
| Loss on Kineta employee separation payments assumed from merger | -$185K | — | — | — | — |
| Total Other Income (Expense) | $1.7M+143.2% | -$4.0M | — | — | — |
| Net Loss | -$30.1M-38.6% | -$21.7M | — | -$29.3M | — |
| Series A Preferred cash dividend | -$8K-300.0% | -$2K+73.9% | -$8K | — | -$8K |
| Deemed dividend on warrant modifications | $0+100.0% | -$965K | — | — | — |
| Net Loss attributable to common stockholders | -$30.1M-32.7% | -$22.6M | — | -$29.3M | — |
| Net Loss per share, basic | -$0.63+47.9% | -$1.21 | — | -$2.47 | — |
| Net Loss per share, diluted | -$0.63+47.9% | -$1.21 | — | -$2.47 | — |
| Weighted-average shares outstanding, basic | $47.9M+156.8% | $18.7M | — | $11.9M | — |
| Weighted-average shares outstanding, diluted | $47.9M+156.8% | $18.7M | — | $11.9M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
TuHURA Biosciences secures $50 million credit facility, extends cash runway to 2028
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?
HURA: 2025 Financial Results